Le Lézard
Classified in: Health, Science and technology
Subject: PDT

Emerson's Next-Generation Software Streamlines Pharmaceutical Development, Accelerates Speed to Market


DeltaV Workflow Management delivers scalable recipe authoring and execution technologies for life sciences companies

ST. LOUIS, April 16, 2024 /PRNewswire/ -- Global automation technology and software leader Emerson (NYSE: EMR) today introduced DeltaVtm Workflow Management, a next-generation software designed for life sciences companies in early-stage development. The new software continues Emerson's expansion of capabilities of the evolving DeltaV automation platform to offer more scalable options to suit the needs of smaller life sciences innovators. For companies with limited IT infrastructure, DeltaV Workflow Management provides a cloud-based, software-as-a-service solution for simple recipe authoring, execution and electronic data capture.

In high-growth life sciences companies, such as those making advanced therapy medicinal products for hard-to-treat diseases and personalized medicines, manufacturing facilities still heavily rely on manual processes and record-keeping for bench-scale operations and recipe authoring. Many do not have robust IT departments, nor staff experienced in the complex coding necessary with traditional manufacturing execution systems.

DeltaV Workflow Management removes this layer of complexity by transitioning recipe workflow data from manual records to digital "paper on glass," providing a simple and scalable solution that helps accelerate the drug development process with no coding experience required. The software also generates searchable digital records that are easily organized and exported and data that can be more easily analyzed and reported. In addition, this digital shift minimizes the contamination risks associated with paper records in sterile clean rooms.

"DeltaV Workflow Management enables innovation for both startups and established labs that demand speed and simplicity in early-stage drug development," said Nathan Pettus, president of Emerson's process systems and solutions business. "Recipes relying on standard, full-blown manufacturing execution systems can take years of experience and months to create and fully automate. With this new software, the timeline is reduced to days, providing companies with a head start toward commercialization and getting new therapeutic medicines into the pipeline faster."

Within DeltaV Workflow Management, users employ simple drag-and-drop elements to create steps for a recipe and automate workflows that meet Good Manufacturing Practice standards. Within those steps, they can add new parameters and e-signature requirements for quality control and regulatory compliance, run product recipes, authorize users for specific tasks and create digital batch records.  

DeltaV Workflow Management expands and complements the user options for digital recipe development and execution already provided by Emerson's DeltaV MES?the newest evolution of the Syncade MES. Users now have additional flexibility to match digital recipe solutions to their business needs, underscoring Emerson's commitment to continuing enhancement of and investment in a portfolio of manufacturing execution solutions for organizations at any scale.

About Emerson 
Emerson (NYSE: EMR) is a global technology and software company providing innovative solutions for the world's essential industries. Through its leading automation portfolio, including its majority stake in AspenTech, Emerson helps hybrid, process and discrete manufacturers optimize operations, protect personnel, reduce emissions and achieve their sustainability goals. For more information, visit Emerson.com.

SOURCE Emerson


These press releases may also interest you

at 07:35
Organon today announced its results for the first quarter ended March 31, 2024. "We entered this year with a clear focus: to deliver our 2024 financial targets while staying true to our mission of improving the health of women, and the first...

at 07:35
Lantern Pharma Inc. , an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced...

at 07:30
Quipt Home Medical Corp. (the "Company") ?, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, announced today that the Toronto Stock Exchange ("TSX") has accepted the Company's notice of intention to implement a...

at 07:30
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will present long-term efficacy, safety and...

at 07:30
MedBright AI Investments Inc. (the "Company" or "MedBright") today announced MedMatrix, a product in which it has a significant investment, has launched two new demonstration videos highlighting the capabilities of the MedMatrix AI Reporter and...

at 07:30
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally...



News published on and distributed by: